ClinicalTrials.gg
RecruitingNCT04424576OMGUpdated Aug 12, 2024

Ovarian Morphology in Girls

An observational study in Amenorrhea, Oligomenorrhea and Puberty, sponsored by Cornell University. Recruiting at 3 sites in United States. Open to female participants aged 9 Years to 17 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-08-12.

Sponsored by Cornell University · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Mar 2025, 1 year 7 months ago, but the record still lists the study as recruiting.
  • Started Jan 2020; still recruiting 6 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
60
Ages
9 Years to 17 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 43 studies in Amenorrhea with a site in United States — 7 open to participants now, 9 under way, 1 of them phase 3. Amenorrhea · United States.

Planned enrollment
12th of 13
60 · median 111
Started
2020
the only one that year
Observational
13 of 43
3 open now
Registered
35th of 43
by date
Lead sponsor
3 of 43
Cornell University

Among the 43 studies in Amenorrhea with a site in United States, this one is the 12th largest by planned enrollment of the 13 observational ones that give a count, is the only one that started in 2020, is one of 13 observational ones, and was the 35th registered.

Amenorrhea

80 studies on the registry are indexed under Amenorrhea; 17 are open to participants now.

Browse Amenorrhea studies →

Open to participants now

7 of the 43 studies in Amenorrhea with a site in United States are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 13 Amenorrhea studies recruiting now, none (0%) set no upper age limit and 11 (85%) stop at 75 or younger; 8 take children under 18; 3 take healthy volunteers.

This study: 9 Years to 17 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies in Amenorrhea with a site in United States, or all of them as a file.
02

Study summary

Establishment of regular menstrual cycles is a key component of reproductive maturation and a recognized vital sign for health and well-being. Irregular menstrual cycles are especially common for the first 2-3 years after an adolescent's first menstrual period (i.e., menarche), which delays the identification and diagnosis of early reproductive disturbances such as polycystic ovary syndrome (PCOS). The purpose of this research study is to determine whether the ovary can serve as a reliable predictor of normal or abnormal development by following the trajectory of ovarian morphology in conjunction with menstrual cyclicity using 3D transabdominal ultrasound imaging in a prospective cohort study of adolescents. A secondary objective is to identify potential environmental factors such as diet and the gut microbiome which influence the trajectory towards normal or abnormal reproductive development.

Read the detailed description

Establishment of regular menstrual cycles is a key component of reproductive maturation and a recognized vital sign for health and well-being. Irregular menstrual cycles are especially common for the first 2-3 years after an adolescent's first menstrual period (i.e., menarche), which delays the identification and diagnosis of early reproductive perturbations and subsequent future disease risk. Therefore, the objectives of this study are to determine whether there are distinct aspects of ovarian morphology that predict the likelihood of regular menses or cycle irregularity at 2y post-menarche and to determine whether diet or lifestyle (such as quality of sleep) contribute to changes in the ovaries and period patterns.

A group of up to 60 adolescents will be enrolled into a prospective longitudinal cohort study. Participants will attend four study visits to their location's respective clinical research center. Study visits will occur at four distinct time points post-menarche: 6-10 months, 11-13 months, 17-19 months, and 23-25 months.

Prior to each of the study visits, participants will undergo one planned 24-hr dietary recall by a member of the research team and self-collect a stool sample.* Participants will be asked to fast the night before the study visit. At each study visit, participants will undergo the following assessments:

A 3D transabdominal ultrasound of the ovaries and uterus.

A fasting blood sample, obtained via venipuncture.

A series of anthropometric assessments, including: height, weight, waist and hip circumference, blood pressure, heart rate, and body fat percentage obtained using a bioimpedance scale.

Tanner stage assessment, using a standardized self-report scoring scheme and by a trained member of the research team who is blinded to the results of the self-reported tanner stage.

Acne scoring, using a standardized scoring scheme by a member of the research team.

Hirsutism assessment, obtained by visually inspecting nine pre-defined regions of the body for terminal hair growth using a standardized scoring scheme by a trained member of the research team.

Urine sample, self-collected by the participant after the transabdominal ultrasound.*

24-hour dietary recall.*

Physical activity questionnaire.*

Two sleep questionnaires, including questions about sleep hygiene, sleep quality, and circadian rhythms.*

In between study visits, participants will maintain menstrual cycle diaries and medication diaries.

*Participants at the University of Rochester site will not complete the urine or stool collection, the dietary recalls, or any of the physical activity and sleep questionnaires.

03

Conditions studied

  • Amenorrhea
  • Oligomenorrhea
  • Puberty

Browse trials for

Keywords

  • Ovary
  • Transabdominal Ultrasound
  • Menarche
  • Periods
  • Microbiome
04

Who can participate

Ages eligible
9 Years to 17 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Female adolescents between the ages of 9 and 17 years who achieved menarche (i.e., very first period) within the past 11 months will be recruited.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female adolescents aged 9 to 17 years
  • Menarche within 11 months of the enrollment visit
  • University of Rochester site only: Family history of PCOS (i.e., mother or aunt)

Exclusion criteria

Exclusion Criteria:

  • Current or recent use of medications or supplements known or suspected to interfere with reproductive or metabolic function in the past 2 months (e.g., , metformin, , anti-seizure medications)
  • Untreated and/or unstable medical or mental health condition known or suspected to interfere with reproductive or metabolic function
  • Currently pregnant or breast feeding
  • History of ovarian surgery
  • Presence of significant acute or chronic illness which may interfere with study participation
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
60 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • Regular Menstrual Cycles

    22 adolescents with regular menstrual cycles (i.e., once every 4-6 weeks) will be enrolled within 11 months of menarche.

  • Irregular Menstrual Cycles

    26 adolescents with irregular menstrual cycles (i.e., \< 4 weeks or \> 6 weeks between periods) will be enrolled within 11 months of menarche.

06

What researchers measure

Primary outcomes

  1. Ovarian size

    Changes in ovarian size over the first 2y post-menarche will be assessed and compared across cohorts.

    Time frame: 24 months

  2. Follicle counts

    Follicle counts, expressed as follicle number per ovary (FNPO) and follicle number per cross-section (FNPS), will be assessed over the first 2y post-menarche and compared across cohorts. Numbers of large follicles (\>10 mm diameter) and small follicles (\<10 mm diameter) will also be compared across cohorts.

    Time frame: 24 months

  3. Menstrual cycle status

    Menstrual cycle status (i.e., regular versus irregular menstrual cycles) will be assessed using menstrual cycle records maintained by participants over the course of the study. Changes in menstrual cycle status over the 2y post-menarche and relationships between menstrual cycle status and other physiological and lifestyle factors will be examined.

    Time frame: 24 months

Secondary outcomes

  1. Body composition

    Changes in percent body fat, obtained using a bioimpedence scale, will be assessed over the first 2y post-menarche and compared across cohorts.

    Time frame: 24 months

  2. Leutenizing hormone (LH), follicle stimulating hormone (FSH), estradiol, progesterone, anti-mullerian hormone, free and total testosterone, and androstenedione

    Serum levels of these reproductive hormones will be assessed over the first 2y post-menarche and compared across cohorts.

    Time frame: 24 months

  3. Sleep quality

    Sleep quality will be assessed using two questionnaires: the Morningness-Eveningness Scale for Children and the Children's Report of Sleep Patterns. Sleep quality will be assessed over the first 2y post-menarche and compared across cohorts.

    Time frame: 24 months

  4. Dietary composition

    Dietary composition (i.e., macro and micronutrient totals, total energy intake) will be assessed using two 24-Hour Food Frequency Questionnaires administered at each gynecological time point.

    Time frame: 24 months

  5. Gut microbiome richness and diversity

    Gut microbiome richness and diversity will be assessed over the first 2y post-menarche and compared across cohorts.

    Time frame: 24 months

07

Study locations

1 of 3 sites recruiting
  • Children's Mercy Hospital
    Kansas City, Missouri 64108, United States
    Completed

    Not enrolling at this site.

  • Cornell University - Human Metabolic Research Unit
    Ithaca, New York 14853, United States
    Completed

    Not enrolling at this site.

  • University of Rochester, Strong Fertility Center
    Rochester, New York 14623, United States
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2020 (actual). Primary completion is estimated for Mar 2025, 62 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 18, 2020
First posted
Jun 11, 2020
StartActual
Jan 31, 2020
Primary completionEst.
Mar 31, 2025
CompletionEst.
Mar 31, 2025
Last update
Aug 12, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 12, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04424576
Lead sponsor
Cornell University
Responsible party
Sponsor
First posted
Jun 11, 2020
Start date
Jan 31, 2020
Primary completion
Mar 31, 2025 (estimated)
Completion
Mar 31, 2025 (estimated)
Last update
Aug 12, 2024

Study contacts

Bailey Smith, MS
Contact
bmd82@cornell.edu
218-308-0560
Marla E Lujan, PhD
Contact
mel245@cornell.edu
607-255-3153
Marla E Lujan, PhD
principal investigator · Cornell University
Tania Burgert, MD
principal investigator · Children's Mercy Hospital Kansas City
Romina Barral, MD MSCR FAPP
principal investigator · Children's Mercy Hospital Kansas City
Kathleen Hoeger, MD
principal investigator · University of Rochester

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion